The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Substance Use and Related Disorders. Part 2: Opioid dependence.

Conclusions. There is enough high quality data to formulate evidence-based guidelines for the treatment of opioid abuse and dependence. This task force report provides evidence for the efficacy of a number of medications to treat opioid abuse and dependence, particularly the opioid agonists methadone or buprenorphine. These medications have great relevance for clinical practice.
PMID: 21486104 [PubMed – in process] (Source: The World Journal of Biological Psychiatry)

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Substance Use and Related Disorders. Part 2: Opioid dependence.

Conclusions. There is enough high quality data to formulate evidence-based guidelines for the treatment of opioid abuse and dependence. This task force report provides evidence for the efficacy of a number of medications to treat opioid abuse and dependence, particularly the opioid agonists methadone or buprenorphine. These medications have great relevance for clinical practice.
PMID: 21486104 [PubMed – in process] (Source: The World Journal of Biological Psychiatry)

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Substance Use and Related Disorders. Part 2: Opioid dependence.

Conclusions. There is enough high quality data to formulate evidence-based guidelines for the treatment of opioid abuse and dependence. This task force report provides evidence for the efficacy of a number of medications to treat opioid abuse and dependence, particularly the opioid agonists methadone or buprenorphine. These medications have great relevance for clinical practice.
PMID: 21486104 [PubMed – in process] (Source: The World Journal of Biological Psychiatry)

An Adverse Reaction to Buprenorphine/Naloxone Induction in Prison: A Case Report

Buprenorphine is an effective treatment for opiate dependence. Prisoners with histories of opiate dependence who are inducted on buprenorphine prior to release are at decreased risk of post-release relapse and overdose, yet many clinicians are unaware of the risks related to buprenorphine induction for non-opiate tolerant patients, especially those on other psychotropic medications. The authors report a case of probable non-lethal overdose during dose induction of a non-tolerant prisoner and discuss appropriate dosing under similar circumstances.
(C) 2011 Lippincott Williams & Wilkins, Inc. (Source: Addictive Disorders and Their Treatment)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

An Adverse Reaction to Buprenorphine/Naloxone Induction in Prison: A Case Report

Buprenorphine is an effective treatment for opiate dependence. Prisoners with histories of opiate dependence who are inducted on buprenorphine prior to release are at decreased risk of post-release relapse and overdose, yet many clinicians are unaware of the risks related to buprenorphine induction for non-opiate tolerant patients, especially those on other psychotropic medications. The authors report a case of probable non-lethal overdose during dose induction of a non-tolerant prisoner and discuss appropriate dosing under similar circumstances.
(C) 2011 Lippincott Williams & Wilkins, Inc. (Source: Addictive Disorders and Their Treatment)

An Adverse Reaction to Buprenorphine/Naloxone Induction in Prison: A Case Report

Buprenorphine is an effective treatment for opiate dependence. Prisoners with histories of opiate dependence who are inducted on buprenorphine prior to release are at decreased risk of post-release relapse and overdose, yet many clinicians are unaware of the risks related to buprenorphine induction for non-opiate tolerant patients, especially those on other psychotropic medications. The authors report a case of probable non-lethal overdose during dose induction of a non-tolerant prisoner and discuss appropriate dosing under similar circumstances.
(C) 2011 Lippincott Williams & Wilkins, Inc. (Source: Addictive Disorders and Their Treatment)

Tipranavir/Ritonavir Induction of Buprenorphine Glucuronide Metabolism in HIV-Negative Subjects Chronically Receiving Buprenorphine/Naloxone.

Conclusions and Scientific Significance: This study further elucidates the effects of TPV/r on glucuronidation. The current evaluation of glucuronide metabolites of BUP and norBUP are suggestive of combined inhibition of Uridine diphosphate (UDP)-glucuronosyltransferase of the 1A family and cytochrome P450 3A4 that spares UGT2B7 leading to a shunting of BUP away from production of norBUP and toward BUP-3G as seen by a statistically significant increase in the AUC of BUP-3G.
PMID: 21438849 [PubMed – as supplied by publisher] (Source: The American Journal of Drug and Alcohol Abuse)

Tipranavir/Ritonavir Induction of Buprenorphine Glucuronide Metabolism in HIV-Negative Subjects Chronically Receiving Buprenorphine/Naloxone.

Conclusions and Scientific Significance: This study further elucidates the effects of TPV/r on glucuronidation. The current evaluation of glucuronide metabolites of BUP and norBUP are suggestive of combined inhibition of Uridine diphosphate (UDP)-glucuronosyltransferase of the 1A family and cytochrome P450 3A4 that spares UGT2B7 leading to a shunting of BUP away from production of norBUP and toward BUP-3G as seen by a statistically significant increase in the AUC of BUP-3G.
PMID: 21438849 [PubMed – as supplied by publisher] (Source: The American Journal of Drug and Alcohol Abuse)

Tipranavir/Ritonavir Induction of Buprenorphine Glucuronide Metabolism in HIV-Negative Subjects Chronically Receiving Buprenorphine/Naloxone.

Conclusions and Scientific Significance: This study further elucidates the effects of TPV/r on glucuronidation. The current evaluation of glucuronide metabolites of BUP and norBUP are suggestive of combined inhibition of Uridine diphosphate (UDP)-glucuronosyltransferase of the 1A family and cytochrome P450 3A4 that spares UGT2B7 leading to a shunting of BUP away from production of norBUP and toward BUP-3G as seen by a statistically significant increase in the AUC of BUP-3G.
PMID: 21438849 [PubMed – as supplied by publisher] (Source: The American Journal of Drug and Alcohol Abuse)